SecurityHCOM / Hawaiian Telcom Holdco, Inc. (420031106)
IndustryCommunications Services, Not Elsewhere Classified
Common Shares Outstanding11,587,963 shares (as of 2017-12-31)
Total Insiders23
Total Directors12
Total Officers5

Stock Insider Trading (from SEC Form 4)

Hawaiian Telcom Holdco, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

HCOM / Hawaiian Telcom Holdco, Inc. insiders include Phillips Bernard R III, CHING MEREDITH J, Haruki Warren H, Twin Haven Special Opportunities Partners IV, LLC, BESSEY DAN T, Reich Robert F Paul Kevin T., Twin Haven Special Opportunities Fund IV, L.P., Deckoff Stephen H, and TWIN HAVEN SPECIAL OPPORTUNITIES FUND III, L.P., Komeiji John T, YEAMAN ERIC K, OLDHAM STEVEN C, Webster Robert, JALKUT RICHARD A, Twin Haven Special Opportunities Partners III, L.L.C., Mellinger Paul, Twin Haven Capital Partners, L.L.C., Barber Scott K, BLACK DIAMOND CAPITAL MANAGEMENT, L.L.C., DODS WALTER A JR, Cellar Kurt Matthew, Fontana Nathel John III, .

Insider Roster

Insider Dir Off 10% Shares Owned
Komeiji John T SVP & General Counsel
X 65,608
BESSEY DAN T SVP & Chief Financial Officer
X 25,573
Barber Scott K Chief Executive Officer, Director
X X 68,569
Paul Kevin T. SVP - Technology
X 23,493
Webster Robert Director, 10% Owner
Twin Haven Special Opportunities Partners III, L.L.C. Director, 10% Owner
Twin Haven Special Opportunities Partners IV, LLC Director, 10% Owner
Twin Haven Capital Partners, L.L.C. Director, 10% Owner
TWIN HAVEN SPECIAL OPPORTUNITIES FUND III, L.P. Director, 10% Owner
Twin Haven Special Opportunities Fund IV, L.P. Director, 10% Owner
Mellinger Paul Director, 10% Owner
X X 2,616,442
Fontana Nathel John III Director
X 3,843
DODS WALTER A JR Director
X 17,923
CHING MEREDITH J Director
X 8,545
Cellar Kurt Matthew Director
X 42,923
OLDHAM STEVEN C Director
X 17,923
YEAMAN ERIC K Director
X 186,365
JALKUT RICHARD A Director
X 22,430
BLACK DIAMOND CAPITAL MANAGEMENT, L.L.C. 10% Owner
Deckoff Stephen H 10% Owner
X
Phillips Bernard R III Director
X
Haruki Warren H Director
X
Twin Haven Capital Partners, L.L.C. Director, 10% Owner
Twin Haven Special Opportunities Fund IV, L.P. Director, 10% Owner
Twin Haven Special Opportunities Partners IV, LLC Director, 10% Owner
Mellinger Paul Director, 10% Owner
Webster Robert Director, 10% Owner
X X
Reich Robert F SVP, CFO and Treasurer
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-03-12 4 Paul Kevin T. F D 27.95 -1,645 23,493
2018-03-12 4 Paul Kevin T. D D -274 25,138
2018-03-12 4 Paul Kevin T. A D 1,348 25,412
2018-03-08 4 Paul Kevin T. A D 3,289 24,064
2018-03-12 4 Barber Scott K F D 27.95 -5,455 68,569
2018-03-12 4 Barber Scott K D D -711 74,024
2018-03-12 4 Barber Scott K A D 4,614 74,735
2018-03-08 4 Barber Scott K A D 15,430 70,121
2018-03-12 4 BESSEY DAN T F D 27.95 -2,331 25,573
2018-03-12 4 BESSEY DAN T A D 2,389 27,904
2018-03-08 4 BESSEY DAN T A D 6,169 25,515
2018-03-12 4 Komeiji John T F D 27.95 -2,567 65,608
2018-03-12 4 Komeiji John T D D -393 68,175
2018-03-12 4 Komeiji John T A D 2,301 68,568
2018-03-08 4 Komeiji John T A D 4,988 66,267
2017-04-27 4 Webster Robert A D 3,843 2,616,442
2017-04-27 4 JALKUT RICHARD A A D 5,188 22,430
2017-04-27 4 YEAMAN ERIC K A D 3,843 186,365
2017-04-27 4 OLDHAM STEVEN C A D 3,843 17,923
2017-04-27 4 Cellar Kurt Matthew A D 3,843 42,923
2017-04-27 4 CHING MEREDITH J A D 3,843 8,545
2017-04-27 4 DODS WALTER A JR A D 3,843 17,923
2017-04-27 4 Fontana Nathel John III A D 3,843 3,843
2017-03-20 4 BLACK DIAMOND CAPITAL MANAGEMENT, L.L.C. See Footnotes J I 1,958 2,651,068
2017-03-20 4 BLACK DIAMOND CAPITAL MANAGEMENT, L.L.C. J D 641 641
2017-03-20 4 Fontana Nathel John III J D -2,599 0
2017-03-13 4 BESSEY DAN T F D 23.46 -1,301 19,346
2017-03-12 4 BESSEY DAN T A D 1,110 20,647
2017-03-09 4 BESSEY DAN T A D 23.30 1,558 19,537
2017-03-09 4 BESSEY DAN T A D 7,482 17,979
2017-03-13 4 Komeiji John T F D 23.46 -2,577 61,279
2017-03-12 4 Komeiji John T D D -463 63,856
2017-03-12 4 Komeiji John T A D 1,162 64,319
2017-03-09 4 Komeiji John T A D 23.30 1,365 63,157
2017-03-09 4 Komeiji John T A D 6,006 61,792
2017-03-13 4 Paul Kevin T. F D 23.46 -1,729 20,775
2017-03-12 4 Paul Kevin T. D D -324 22,504
2017-03-12 4 Paul Kevin T. A D 680 22,828
2017-03-09 4 Paul Kevin T. A D 23.30 739 22,148
2017-03-09 4 Paul Kevin T. A D 3,960 21,409
2017-03-13 4 Barber Scott K F D 23.46 -4,878 54,691
2017-03-12 4 Barber Scott K D D -839 59,569
2017-03-12 4 Barber Scott K A D 2,088 60,408
2017-03-09 4 Barber Scott K A D 23.30 3,185 58,320
2017-03-09 4 Barber Scott K A D 18,581 55,135
2016-09-29 4 YEAMAN ERIC K S D 22.1865 -9,099 168,587 3,740,355
2016-09-28 4 YEAMAN ERIC K S D 22.6502 -4,901 177,686 4,024,623
2016-07-14 4 Haruki Warren H F D -2,298 11,782
2016-07-14 4 Phillips Bernard R III F D -2,298 14,782
2016-07-13 4 Webster Robert A D 2,599 2,612,599
2016-07-13 4 Fontana Nathel John III A D 2,599 2,599
2016-06-28 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 21.0064 12,200 2,610,000 54,826,704
2016-06-27 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 20.47 11,373 2,597,800 53,176,966
2016-06-27 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 20.4503 1,000 2,586,427 52,893,208
2016-06-24 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 20.2999 10,927 2,585,427 52,483,910
2016-06-24 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 20.3429 7,300 2,574,500 52,372,796
2016-06-23 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 20.4536 2,200 2,567,200 52,508,482
2016-06-15 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 19.6631 49,679 2,565,000 50,435,852
2016-03-12 4 Paul Kevin T. F D 23.07 -1,345 35,333
2016-03-12 4 Paul Kevin T. D D -405 35,333
2016-03-12 4 BESSEY DAN T F D 23.07 -477 21,471
2016-03-10 4 BESSEY DAN T P D 21.65 250 21,471 464,847
2016-03-12 4 Barber Scott K F D 23.07 -3,125 73,948
2016-03-12 4 Barber Scott K D D -840 73,948
2016-03-12 4 Komeiji John T F D 23.07 -2,543 112,403
2016-03-12 4 Komeiji John T D D -831 112,403
2016-03-03 4 Barber Scott K A D 11,844 40,519
2016-03-03 4 BESSEY DAN T A D 5,990 10,724
2016-03-03 4 JALKUT RICHARD A A D 4,070 18,587
2016-03-03 4 Cellar Kurt Matthew A D 2,646 39,080
2016-03-03 4 DODS WALTER A JR A D 2,646 14,080
2016-03-03 4 Haruki Warren H A D 2,646 14,080
2016-03-03 4 OLDHAM STEVEN C A D 2,646 14,080
2016-03-03 4 CHING MEREDITH J A D 2,646 4,702
2016-03-03 4 YEAMAN ERIC K A D 2,646 182,587
2016-03-03 4 Komeiji John T A D 5,342 59,160
2016-03-03 4 Phillips Bernard R III A D 2,646 17,080
2016-03-03 4 Paul Kevin T. A D 3,146 19,214
2016-02-29 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 23.8713 5,852 4,526,111 108,044,154
2016-02-29 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 24.00 50,000 4,526,111 108,626,664
2016-02-26 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.5992 1,233 4,526,111 102,286,488
2016-02-25 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.497 1,500 3,457,972 77,793,996
2016-02-24 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.3167 1,744 3,457,972 77,170,524
2016-01-08 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 23.91 100 2,454,992 58,698,859
2016-01-04 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 23.9774 192 2,454,892 58,861,927
2015-12-31 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 24.8981 3,700 2,454,700 61,117,366
2015-12-01 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 24.2979 101,163 2,451,000 59,554,153
2015-12-01 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 24.2298 500 2,349,837 56,936,081
2015-11-25 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.7521 2,000 2,349,337 53,452,350
2015-11-24 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 23.00 2,361 2,347,337 53,988,751
2015-11-23 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 23.049 18,000 2,344,976 54,049,352
2015-11-20 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 23.0051 8,000 2,326,976 53,532,316
2015-11-20 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 23.0789 8,000 2,318,976 53,519,415
2015-11-02 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 23.00 60,670 2,310,976 53,152,448
2015-10-27 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.5 800 2,250,306 50,631,885
2015-10-15 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.5 2,030 2,249,506 50,613,885
2015-10-14 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.50 2,689 2,247,476 50,568,210
2015-10-13 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.5 287 2,244,787 50,507,708
2015-10-08 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.1916 3,215 2,244,500 49,809,046
2015-09-24 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 21.20 52,219 2,241,285 47,515,242
2015-09-22 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 21.00 500 2,189,066 45,970,386
2015-09-18 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 21.2242 4,000 2,188,566 46,450,562
2015-09-10 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 21.33 10,100 2,184,566 46,596,793
2015-09-11 4 JALKUT RICHARD A G D -5,000 14,517
2015-09-04 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 21.3431 1,800 2,174,466 46,409,845
2015-08-25 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.05 2,090 2,172,666 47,907,285
2015-08-20 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.33 3,000 2,170,576 48,468,962
2015-08-20 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.5 1,121 2,167,576 48,770,460
2015-08-19 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.7975 1,275 2,166,455 49,389,758
2015-08-14 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.6315 6,000 2,165,180 49,001,271
2015-08-11 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 22.8762 2,000 2,159,180 49,393,834
2015-08-04 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 23.8087 6,000 2,157,180 51,359,651
2015-08-01 4 Paul Kevin T. F D 24.90 -340 16,068
2015-07-28 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 24.4226 3,345 2,151,180 52,537,409
2015-07-27 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 24.4875 10,620 2,147,835 52,595,110
2015-07-17 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 25.00 25,000 2,137,215 53,430,375
2015-07-16 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 25 3 2,112,215 52,805,375
2015-07-15 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 24.9931 3,212 2,112,212 52,790,726
2015-07-13 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 25 255 2,109,000 52,725,000
2015-07-09 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 25 1,439 2,108,745 52,718,625
2015-07-08 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 25 306 2,107,306 52,682,650
2015-06-22 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 25 42,128 2,107,000 52,675,000
2015-06-20 4 YEAMAN ERIC K A D 1,876 179,941
2015-06-20 4 YEAMAN ERIC K F D -78,925 178,065
2015-06-20 4 Barber Scott K A D 2,102 28,675
2015-06-17 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 25.15 100 2,064,872 51,931,531
2015-06-16 4 Twin Haven Capital Partners, L.L.C. See Footnotes P I 25.5143 5,000 2,017,000 51,462,343
2015-06-16 4 Twin Haven Capital Partners, L.L.C. See footnotes X I 14.00 47,772 2,064,772
2015-06-04 4 Twin Haven Capital Partners, L.L.C. See Footnotes P I 25.00 74,079 2,012,000 50,300,000
2015-05-11 4 BESSEY DAN T A D 4,516 4,516
2015-05-01 4 CHING MEREDITH J A D 2,056 2,056
2015-05-26 4 Twin Haven Capital Partners, L.L.C. See Footnotes P I 25.00 10,000 1,937,921 48,448,025
2015-05-08 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 25.5195 2,500 1,927,921 49,199,580
2015-05-08 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 25.4995 50,000 1,925,421 49,097,273
2015-05-07 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 25.5919 5,000 1,875,421 47,995,587
2015-05-07 4 Twin Haven Capital Partners, L.L.C. See Footnotes P I 25.50 817 1,870,421 47,695,736
2015-05-05 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 25.9729 5,000 1,869,604 48,559,038
2015-05-05 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 26.0962 10,815 1,864,604 48,659,079
2015-05-04 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 26.26 800 1,853,789 48,680,499
2015-05-04 4 Twin Haven Capital Partners, L.L.C. See Footnotes P I 26.25 3,063 1,852,989 48,640,961
2015-05-01 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 26.2816 2,040 1,849,926 48,619,015
2015-04-30 4 Twin Haven Capital Partners, L.L.C. See Footnotes P I 26.25 286 1,847,886 48,507,008
2015-04-27 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 26.25 200 1,847,600 48,499,500
2015-04-24 4 Twin Haven Capital Partners, L.L.C. See Footnotes P I 26.25 400 1,847,400 48,494,250
2015-03-30 4 Twin Haven Capital Partners, L.L.C. See Footnotes P I 26.35 7,000 1,847,000 48,668,450
2015-03-28 4 Reich Robert F D D -15,412 37,962
2015-03-25 4 Twin Haven Capital Partners, L.L.C. See Footnotes P I 26.15 10,000 1,840,000 48,116,000
2015-03-24 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 26.11 19,000 1,830,000 47,781,300
2015-03-23 4 Twin Haven Capital Partners, L.L.C. See Footnotes P I 26.15 17,800 1,811,000 47,357,650
2015-03-19 4 Twin Haven Capital Partners, L.L.C. See footnotes P I 26.00 8,000 1,793,200 46,623,200
2015-03-18 4 Twin Haven Capital Partners, L.L.C. See Footnotes P I 25.9948 25,000 1,785,200 46,405,917
2015-03-12 4 Paul Kevin T. F D 26.00 -1,442 16,408
2015-03-12 4 Paul Kevin T. D D -194 17,850
2015-03-12 4 Barber Scott K F D 26.00 -1,952 26,573
2015-03-12 4 Barber Scott K D D -189 28,525
2015-03-12 4 YEAMAN ERIC K F D 26.0 -16,775 256,990
2015-03-12 4 YEAMAN ERIC K D D -2,730 273,765
2015-03-12 4 Komeiji John T F D 26.00 -3,616 53,818
2015-03-12 4 Komeiji John T D D -585 57,434
2015-03-12 4 Reich Robert F F D 26.00 -3,968 53,374
2015-03-12 4 Reich Robert F D D -622 57,342
2015-03-09 4 Komeiji John T A D 4,951 58,019
2015-03-09 4 Phillips Bernard R III A D 2,498 14,434
2015-03-09 4 Cellar Kurt Matthew A D 2,498 36,434
2015-03-09 4 Paul Kevin T. A D 2,899 18,044
2015-03-09 4 Haruki Warren H A D 2,498 11,434
2015-03-09 4 YEAMAN ERIC K A D 13,934 276,495
2015-03-09 4 DODS WALTER A JR A D 2,498 11,434
2015-03-09 4 Barber Scott K A D 6,796 28,714
2015-03-09 4 OLDHAM STEVEN C A D 2,498 11,434
2015-03-09 4 JALKUT RICHARD A A D 3,843 19,517
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...